The collaborative founder of the Groupon Company Eric Lefkofsky is also the CEO of multiple other startup companies that he has either founded or co-founded. One such startup company is Tempus. Tempus is a technology company that has recently started focusing on supplying medical doctors of the University of Chicago with the data and tools they need to aid patients suffering from breast cancer. The added service of Tempus is due to the partnership between Erik Lefkofsky and the University of Chicago. Other companies Eric Lefkofsky have aided establishing include Lightbank, Inner Workings, Mediaocean, Uptake Technologies and Echo Global Logistics.
Eric Lefkofsky has been very dedicated to philanthropy. He is a part of many charitable organizations. In 2002 the Lefkofsky family established their own charity foundation – the Lefkofsky Family Foundation. The Lefkofsky Family Foundation has the mission of giving back to the community of Chicago and to make the city a happier place for its citizens. The foundation was founded by Eric Lefkofsky and his wife, Liz. Lefkofsky is part of the Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, and of The Museum of Science and Industry and World Business Chicago, and he is a Trustee of those organizations. Erik Lefkofsky has also been teaching at the University of Chicago for some years now, and he also wrote the book Accelerated Disruption. Lefkofsky graduated with a Juris Doctor from the University of Michigan – School of Law.
Tempus and the University of Chicago – College of Medicine have joined forces in order to conduct extensive research and collect data on breast cancer that will allow Tempus to create new treatment methods for breast cancer patients. According to Dr Olufunmilayo Olopade of the University of Chicago Breast Cancer is one of the most widely spread forms of the disease. However, there is all too little data on it. Tempus will be doing various analyses and as a result, will create personalized plans that will lead to more effective treatments for the patients. Both Tempus and the doctors and the University of Chicago have a hopeful outlook on their partnership.